January 2024
1. MINGUEZ-OLAONDO A, Lopez-Bravo A, Quintas S, Nieves-Castellanos C, et al
   [New therapeutic era for migraine attacks with recently approved monoclonal antibodies, ditans and gepants].
   Rev Neurol. 2024;78:47-57.
   

   >> Share

   
   October 2023
2. VINUEZA-BUITRON P, Montes-Pena VJ, Rodriguez-Mena D, Boada-Cuellar JL, et al
   [Habituation deficit study in patients with episodic migraine thru nociceptive blink reflex].
   Rev Neurol. 2023;77:159-165.
   

   >> Share

   
   June 2023
3. GUEVARA-MARTINEZ E, Arjona-Padillo A
   [Complete remission of a migraine after treatment with cisplatin].
   Rev Neurol. 2023;76:375.
   

   >> Share

   
   May 2023
4. PEREZ-RODRIGUEZ A, Bandres-Hernandez P, Anciones C, Terron-Cuadrado C, et al
   [Cardiovascular safety of new drugs for the acute and preventive treatment of migraine: gepants and ditans].
   Rev Neurol. 2023;76:295-308.
   

   >> Share

   
   April 2023
5. MADERA J, Rodriguez-Rodriguez EM, Gonzalez-Quintanilla V, Perez-Pereda S, et al
   [Peripheral stimulation of the trigeminal nerve by nasopharyngeal swabbing as a possible trigger of migraine attacks].
   Rev Neurol. 2023;76:227-233.
   

   >> Share

   
   March 2023
6. FRESAN-RESTITUTO D, Lacalle-Fabo E, Martin-Bujanda M, Sarobe-Carricas MT, et al
   Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one.
   Rev Neurol. 2023;76:213-216.
   

   >> Share

   
   January 2023
7. DA SILVA CARDOSO J, Curto C, Manuel-Vieira P, Ashworth J, et al
   Primary headache with onset in childhood and adolescence: natural history and prognostic factors in a Portuguese population.
   Rev Neurol. 2023;76:9-14.
   

   >> Share

   
   August 2022
8. LOPEZ-MORENO Y, Castro-Sanchez MV, Garcia-Trujillo L, Serrano-Castro P, et al
   [Failure of an anti-CGRP monoclonal antibody in the treatment of migraine. Is it worthwhile trying another one?]
   Rev Neurol. 2022;75:87-91.
   

   >> Share

   
   July 2022
9. FERNANDEZ-GARZA LE, Marfil A
   Comorbidity between hypothyroidism and headache disorders in a Mexican population.
   Rev Neurol. 2022;75:13-16.
   

   >> Share

   
   May 2022
10. JUICA-AVELLO S, Riquelme-Vergara C, Condeza-Riquelme F, Gonzalez-Burboa A, et al
    [Comparison of tiapride and topiramate in the prophylactic treatment of chronic migraine: a randomised, double-blind, pilot study].
    Rev Neurol. 2022;74:325-330.
    

    >> Share

    
    January 2022
11. CASO-GONZALEZ A, Leralta-Gonzalez C, Sanz-Alonso V, Iturbe-Heras M, et al
    [Clinical experience with erenumab during the first year of treatment].
    Rev Neurol. 2022;74:8-14.
    

    >> Share

    
    June 2021
12. LAINEZ-ANDRES JM, Ashina M, Belvis R, Diaz-Insa S, et al
    1st Post-European Headache Federation Meeting: a review of the latest developments presented at the 2020 European Headache Federation Congress.
    Rev Neurol. 2021;72.
    

    >> Share

    
    
13. MARIN-GRACIA M, Hernando-Quintana N, Lopez-Bravo A, Garcia-Arguedas C, et al
    [Degree of compliance with treatment at three months in migraine patients].
    Rev Neurol. 2021;72:377-383.
    

    >> Share

    
    February 2021
14. MARTINEZ-PIAS E, Garcia-Azorin D, Trigo-Lopez J, Sierra A, et al
    [Chronic migraine with daily headache. Literature review].
    Rev Neurol. 2021;72:133-140.
    

    >> Share

    
    December 2020
15. PLANCHUELO-GOMEZ A, Garcia-Azorin D, Guerrero-Peral AL, Aja-Fernandez S, et al
    [Response prediction for chronic migraine preventive treatment by gray matter morphometry in magnetic resonance imaging: a pilot study].
    Rev Neurol. 2020;71:399-406.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share